看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- _( e/ `/ p, f. _7 a8 a
! l1 U( w' ^: { [- B$ \4 _, t, X9 }" R
Currently available feasibility data for possible combination strategies.
8 D) t4 Z- |0 h7 i4 {————————————————————————————————
3 R6 S9 x2 w' M' O2 z C' O6 _Combination Feasibility according to preliminary data
7 i2 e, b* r5 f4 d2 C——————————————————————————————————& c; \- N( t- G7 k$ \* R
Bevacizumab + sorafenib Yes, reduced dose
( T; c4 U5 ]: H" f% q: _; NBevacizumab + sunitinib† No : e7 E6 M% e3 B# u
Bevacizumab + temsirolimus Yes
: I( X: ~6 R6 H; ^! @Bevacizumab + everolimus Yes
) ^, K, X- i! Y. fSorafenib + sunitinib ? 2 d" i) u; L! B/ U3 c
Sorafenib + temsirolimus Yes, reduced dose / b9 C' a( K8 h' |
Sorafenib + everolimus Yes, reduced dose
2 W% t _& z; M5 M0 JSunitinib + temsirolimus† No
8 G+ A9 `5 u* h9 V! z5 ISunitinib + everolimus ?
- n1 u: Y( P* |9 BTemsirolimus + everolimus ?
% M% N$ Z1 i# D3 D! A/ `. R |- H————————————————————; g& ?; ]+ W3 G0 U; _
†Led to US FDA warning.4 O4 l% P$ s; ?3 p0 o
?: As yet unattempted combination.
9 G9 ` K8 Z& @& q* \% j |
显身卡
